Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Sep 21, 2009; 15(35): 4415-4422
Published online Sep 21, 2009. doi: 10.3748/wjg.15.4415
Published online Sep 21, 2009. doi: 10.3748/wjg.15.4415
Table 3 Distribution of patients by chemotherapy regimen and treatment setting 1n (%)
| Chemotherapy regimen | Neoadjuvant (n = 84) | Adjuvant (n = 213) | First-line (n = 743) | Second-line (n = 354) | Any setting (n = 1013) |
| All 5-FU-based regimens | 51 (60.7) | 140 (65.7) | 319 (42.9) | 139 (39.3) | 540 (53.5) |
| 5-FU monotherapy | 16 (19.0) | 104 (48.8) | 89 (12.0) | 68 (19.2) | 257 (25.4) |
| 5-FU + platinum | 24 (28.6) | 19 (8.9) | 104 (14.0) | 25 (7.1) | 163 (16.1) |
| 5-FU + platinum + non-platinum | 14 (16.7) | 18 (8.5) | 96 (12.9) | 31 (8.8) | 145 (14.3) |
| 5-FU + non-platinum | 2 (2.4) | 5 (2.3) | 30 (4.0) | 40 (11.3) | 73 (7.2) |
| Capecitabine-based regimens | 4 (4.8) | 24 (11.3) | 90 (12.1) | 72 (20.3) | 166 (16.4) |
| Capecitabine monotherapy | 2 (2.4) | 18 (8.5) | 50 (6.7) | 42 (11.9) | 105 (10.4) |
| Capecitabine + platinum | 2 (2.4) | 1 (0.5) | 11 (1.5) | 8 (2.3) | 19 (1.9) |
| Capecitabine + platinum + non-platinum | 0 (0.0) | 6 (2.8) | 16 (2.2) | 11 (3.1) | 31 (3.1) |
| Capecitabine + non-platinum | 0 (0.0) | 1 (0.5) | 13 (1.7) | 19 (5.4) | 32 (3.2) |
- Citation: Saif MW, Shi N, Zelt S. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol 2009; 15(35): 4415-4422
- URL: https://www.wjgnet.com/1007-9327/full/v15/i35/4415.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.4415